<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 10-K/A

                                (AMENDMENT NO. 1)


  [X] Annual report pursuant to section 13 or 15(d) of the Securities Exchange
             Act of 1934 for the fiscal year ended December 31, 2002

                                       or

     [ ] Transition report pursuant to section 13 or 15(d) of the Securities
                              Exchange Act of 1934

                         Commission file number 0-24517

                                 ORTHOVITA, INC.
             (Exact name of registrant as specified in its charter)

                                  PENNSYLVANIA
                         (State or other jurisdiction of
                         incorporation or organization)

                                   23-2694857
                      (I.R.S. Employer Identification No.)

                             45 Great Valley Parkway
                              Malvern, Pennsylvania
                    (Address of principal executive offices)

                                      19355
                                   (Zip Code)

       Registrant's telephone number, including area code: (610) 640-1775

        Securities registered pursuant to Section 12(b) of the Act: None

           Securities registered pursuant to Section 12(g) of the Act:
           -----------------------------------------------------------
             Common Stock, par value $.01 per share (Title of class)

Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in the

<PAGE>

definitive proxy statement incorporated by reference in Part III of this annual
report on Form 10-K or any amendment to this annual report on Form 10-K. [X]

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Act). Yes [ ] No [X]


As of June 28, 2002, the aggregate market value of the Common Stock held by
non-affiliates of the registrant was $25,472,947. Such aggregate market value
was computed by reference to the closing sale price of the Common Stock as
reported on the Nasdaq National Market on such date. For purposes of making this
calculation only, the registrant has defined affiliates as including all
directors, executive officers and beneficial owners of more than ten percent of
the registrant's Common Stock.


As of March 24, 2003, there were 20,748,865 shares of the registrant's Common
Stock outstanding.

                      DOCUMENTS INCORPORATED BY REFERENCE:

Portions of Orthovita, Inc.'s Proxy Statement relating to the 2003 Annual
Meeting of Shareholders (to be filed within 120 days after the end of the fiscal
year covered by this annual report on Form 10-K) are incorporated into Part III
of this annual report on Form 10-K by reference.

Portions of Orthovita, Inc.'s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2002 filed with the Commission on November 19, 2002 are
incorporated into Part I of this annual report on Form 10-K by reference.

<PAGE>




This amendment to Orthovita's Form 10-K for the fiscal year ended December 31,
2002 amends and modifies the Form 10-K to amend and restate in their entirety
Exhibit 23.1 and the Exhibit Index.

ITEM 15.      EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K.


<PAGE>




(c) Exhibits

The following is a list of exhibits filed as part of this annual report on Form
10-K. Where so indicated, exhibits which were previously filed are incorporated
by reference. For exhibits incorporated by reference, the location of the
exhibit in the previous filing is indicated in parentheses.

3.1    Amended and Restated Articles of Incorporation of the Company (3)
3.2    Amended and Restated Bylaws of the Company (3)
3.3    Bylaw Amendment (17)
4.1  Specimen of Common Stock Certificate of the Company (10)
4.2  Statement of Designation of Series A 6% Adjustable Cumulative Convertible
Voting Preferred Stock (15)
4.3  Registration Rights Agreement dated August 22, 2000 among the Company,
Brown Simpson Partners I, Ltd., Janney Montgomery Scott LLC, Emerging Growth
Equities, Ltd. and VFT Special Ventures Ltd. (4)
4.4  Registration Rights Agreement among the Company, Emerging Growth Equities,
Ltd. and each of the investors named therein (6)
4.5  Registration Rights Agreement dated March 29, 2001 between the Company and
Japan Medical Dynamic Marketing, Inc. (6)
4.6  Registration Rights Agreement dated December 20, 2001 among the Company,
SDS Merchant Fund, L.P. and S.A.C. Capital Associates, LLC (8)
4.7  Investor Rights Agreement dated as of July 19, 2002 between the Company and
the other parties named therein. (15)
4.8  Warrant to Purchase Shares of Common Stock dated as of November 3, 1999 in
favor of Progress Capital, Inc. (10)
4.9  Warrant to Purchase 31,779 Shares of Common Stock dated August 22, 2000 in
favor of Janney Montgomery Scott LLC (4)
4.10 Warrant to Purchase 31,780 Shares of Common Stock dated August 22, 2000 in
favor of VFT Special Ventures Ltd. (4)
4.11 Warrant to Purchase 566,894 Shares of Common Stock dated January 18, 2001
in favor of Rennes Fondation (10)
4.12 Warrant to Purchase 59,250 Shares of Common Stock dated March 19, 2001 in
favor of Emerging Growth Equities, Ltd. (5)
4.13 Warrant to Purchase 22,200 Shares of Common Stock dated April 27, 2001 in
favor of Emerging Growth Equities, Ltd. (6)

<PAGE>

4.14 Form of Warrant to Purchase Shares of Common Stock dated May 18, 2001
granted to S.A.C. Capital Associates, LLC and SDS Merchant Fund, L.P. (7)
4.15 Warrant to Purchase 50,000 Shares of Common Stock dated October 23, 2001 in
favor of Tucker Anthony Incorporated (11)
4.16 Form of Warrant issuable to the Purchasers of Series A 6% Adjustable
Cumulative Convertible Voting Preferred Stock (16)
4.17 Form of Warrant issued to the Designees of Placement Agent SmallCaps Online
Group, LLC (15)

*10.1   Employment Letter dated as of March 12, 1999 by and between the Company
and Dr. Maartin Persenaire (19)

*10.2   Employment Agreement dated as of December 31, 1999 by and between the
Company and David Joseph (10)
*10.3   Addendum to Employment Agreement dated as of January 1, 2002 between the
Company and David S. Joseph (11)
*10.4   Employment Agreement dated as of January 1, 2002 by and between the
Company and Erik M. Erbe (11)

*10.5   Employment Agreement dated as of May 10, 2002 by and between the
Company and Erik M. Erbe (14)
*10.6   Employment Agreement dated as of May 10, 2002 by and between the
Company and Antony Koblish (14)
*10.7   Employment Agreement dated as of May 10, 2002 by and between the
Company and Joseph M. Paiva (14)
*10.8   Change of Control Agreement dated as of April 23, 2001 between the
Company and David McIlhenny (19)

*10.9   1993 Stock Option Plan (3)
*10.10  Amended and Restated 1997 Equity Compensation Plan (18)
*10.11  Amended and Restated Employee Stock Purchase Plan (3)
10.12   Master Equipment Lease Agreement dated as of July 11, 1997 between the
Company and Finova Technology Finance, Inc. (2)
10.13   Amendment to the Master Equipment Lease Agreement dated as of April 15,
1999 between the Company and Finova Technology Finance, Inc. (9)
10.14   Revenue Interests Assignment Agreement dated as of October 16, 2001
among Vita Special Purpose Corp., the Company and Paul Capital Royalty
Acquisition Fund, L.P. (portions of this document have been omitted pursuant to
the Company's confidential treatment request under Exchange Act Rule 24b-2)(13)
10.15   Amendment to Revenue Interests Assignment Agreement and Stock Purchase
Agreement dated March 22, 2002 among the Company, Paul Capital Royalty
Acquisition Fund, L.P. and Vita Special Purpose Corp. (11)
10.16   Assignment dated as of October 16, 2001 between Vita Special Purpose
Corp. and Paul Capital Royalty Acquisition Fund, L.P. (12)
10.17   Security Agreement dated as of October 16, 2001 between Vita Special
Purpose Corp. and Paul Capital Royalty Acquisition Fund, L.P. (12)
10.18   Pledge Agreement dated as of October 16, 2001 between Vita Licensing,
Inc. and Paul Capital Royalty Acquisition Fund, L.P. (12)
10.19   Stock Purchase Agreement dated as of October 16, 2001 between the
Company and Paul Capital Royalty Acquisition Fund, L.P. (12)

<PAGE>

10.20   Third Amendment to Line of Credit, Term Loan and Security Agreement
dated October 25, 2000 between the Company and Progress Bank (10)
10.21   Capital Expenditure Loan Note dated October 25, 2000 between the Company
and Progress Bank (10)
10.22   Asset Sale Agreement dated as of February 10, 2000 between the Company
and Implant Innovations, Inc. (9)
10.23   Development and Distribution Agreement dated March 29, 2001 between the
Company and Japan Medical Dynamic Marketing, Inc. (11)
10.24   Subscription Agreement dated July 10, 2000 between the Company and
Rennes Fondation (10)
10.25   Subscription Agreement dated August 22, 2000 between the Company and
Brown Simpson Partners I, Ltd. (4)
10.26   Subscription Agreement dated as of October 4, 2000 between the Company
and Raimund Gabriel (10)
10.27   Subscription Agreement dated as of January 18, 2001 between the Company
and Rennes Fondation (10)
10.28   Form of Subscription Agreement between the Company and each of the
purchasers named therein (6)
10.29   Subscription Agreement dated March 29, 2001 between the Company and
Japan Medical Dynamic Marketing, Inc. (6)

10.30   Subscription Agreement dated as of December 20, 2001 between the Company
and S.A.C. Capital Associates, LLC (8)

10.31   Subscription Agreement dated as of December 20, 2001 between the Company
and SDS Merchant Fund, L.P. (8)

10.32   Preferred Stock and Warrant Purchase Agreement dated as of July 19, 2002
        between the Company and the Purchasers named therein (16)
10.33   Master Security Agreement dated as of October 4, 2001 between the
        Company and General Electric Capital Corporation (19)
10.34   Form of Promissory Note relating to Master Security Agreement dated as
        of October 4, 2001 between the Company and General Electric Capital
        Corporation (19)
21.1    Subsidiaries (19)

23.1    Consent of KPMG LLP (1)

99.1    Certifications Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (19)
99.2    Certifications Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 (19)


----------
(1)  Filed herewith.
(2)  Filed as an Exhibit to the Company's Registration Statement on Form S-1
(File No. 333-51689) filed on May 1, 1998 and incorporated herein by reference.
(3)  Filed as an Exhibit to Amendment No. 3 to the Company's Registration
Statement on Form S-1 (File No. 333-51689) filed on June 15, 1998 and
incorporated herein by reference.
(4)  Filed as an Exhibit to the Company's Registration Statement on Form S-3
(File No. 333-47386) filed on October 5, 2000 and incorporated herein by
reference.
(5)  Filed as an Exhibit to the Company's Registration Statement on Form S-3
(File No. 333-59288) filed on April 20, 2001 and incorporated herein by
reference.


<PAGE>

(6)  Filed as an Exhibit to Amendment No. 1 to the Company's Registration
Statement on Form S-3 (File No. 333-59288) filed on May 4, 2001 and incorporated
herein by reference.
(7)  Filed as an Exhibit to Amendment No. 2 to the Company's Registration
Statement on Form S-3 (File No. 333-59288) filed on May 24, 2001 and
incorporated herein by reference.
(8)  Filed as an Exhibit to the Company's Registration Statement on Form S-3
(File No. 333-84632) filed on March 20, 2002 and incorporated herein by
reference.
(9)  Filed as an Exhibit to the Company's Annual Report on Form 10-K for the
year ended December 31, 1999 and incorporated herein by reference.
(10) Filed as an Exhibit to the Company's Annual Report on Form 10-K for the
year ended December 31, 2000 and incorporated herein by reference.
(11) Filed as an Exhibit to the Company's Annual Report on Form 10-K for the
year ended December 31, 2001 and incorporated herein by reference.
(12) Filed as an Exhibit to the Company's Current Report on Form 8-K filed on
November 13, 2001 and incorporated herein by reference.
(13) Filed as an Exhibit to the Company's Current Report on Form 8-K/A filed on
November 27, 2001 and incorporated herein by reference.
(14) Filed as an Exhibit to the Company's Current Report on Form 8-K filed on
June 13, 2002 and incorporated herein by reference.
(15) Filed as an Exhibit to the Company's Current Report on Form 8-K filed on
July 23, 2002 and incorporated herein by reference.
(16) Filed as an Exhibit to the Amendment to the Company's Current Report on
Form 8-K filed on July 31, 2002 and incorporated herein by reference.
(17) Filed as an Exhibit to the Company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2002 and incorporated herein by reference.
(18) Filed as an Exhibit to the Company's Registration Statement on Form S-8
(File No. 333-100034) filed on September 24, 2002 and incorporated herein by
reference.

(19) Previously filed.


*    Constitutes management contract or compensatory plan or arrangement
required to be filed as an exhibit to this form.

Copies of the exhibits are available to shareholders (upon payment of a $.20 per
page fee to cover the Company's expenses in furnishing the exhibits) from
Investor Relations, Orthovita, Inc., 45 Great Valley Parkway, Malvern,
Pennsylvania 19355.


<PAGE>

                                   SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                                          ORTHOVITA, INC.

Date: March 31, 2003

                                          /s/  ANTONY KOBLISH
                                          By:  Antony Koblish
                                          Chief Executive Officer and President




<PAGE>

                                 ORTHOVITA, INC.

                           CERTIFICATIONS PURSUANT TO
                                 SECTION 302 OF
                         THE SARBANES-OXLEY ACT OF 2002

I, Antony Koblish, certify that:

     1.   I have reviewed this annual report on Form 10-K of Orthovita, Inc.;

     2.   Based on my knowledge, this annual report does not contain any untrue
          statement of a material fact or omit to state a material fact
          necessary to make the statements made, in light of the circumstances
          under which such statements were made, not misleading with respect to
          the period covered by this annual report;

     3.   Based on my knowledge, the financial statements, and other financial
          information included in this annual report, fairly present in all
          material respects the financial condition, results of operations and
          cash flows of the registrant as of, and for, the periods presented in
          this annual report;

     4.   The registrant's other certifying officers and I are responsible for
          establishing and maintaining disclosure controls and procedures (as
          defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant
          and we have:

          a)     designed such disclosure controls and procedures to ensure that
               material information relating to the registrant, including its
               consolidated subsidiaries, is made known to us by others within
               those entities, particularly during the period in which this
               annual report is being prepared;

          b)     evaluated the effectiveness of the registrant's disclosure
               controls and procedures as of a date within 90 days prior to the
               filing date of this annual report (the "Evaluation Date"); and

          c)     presented in this annual report our conclusions about the
               effectiveness of the disclosure controls and procedures based on
               our evaluation as of the Evaluation Date;

     5.   The registrant's other certifying officers and I have disclosed, based
          on our most recent evaluation, to the registrant's auditors and the
          audit committee of registrant's board of directors (or persons
          performing the equivalent function):

          a)   all significant deficiencies in the design or operation of
               internal controls which could adversely affect the registrant's
               ability to record, process, summarize and report financial data
               and have identified for the registrant's auditors any material
               weaknesses in internal controls; and

          b)   any fraud, whether or not material, that involves management or
               other

<PAGE>

          c)   employees who have a significant role in the registrant's
               internal controls; and

     6.   The registrant's other certifying officers and I have indicated in
          this annual report whether or not there were significant changes in
          internal controls or in other factors that could significantly affect
          internal controls subsequent to the date of our most recent
          evaluation, including any corrective actions with regard to
          significant deficiencies and material weaknesses.

/s/ Antony Koblish

Antony Koblish
President and Chief Executive Officer

March 31, 2003


<PAGE>

                                 ORTHOVITA, INC.

                           CERTIFICATIONS PURSUANT TO
                                 SECTION 302 OF
                         THE SARBANES-OXLEY ACT OF 2002

I, Joseph M. Paiva, certify that:

     1.   I have reviewed this annual report on Form 10-K of Orthovita, Inc.;

     2.   Based on my knowledge, this annual report does not contain any untrue
          statement of a material fact or omit to state a material fact
          necessary to make the statements made, in light of the circumstances
          under which such statements were made, not misleading with respect to
          the period covered by this annual report;

     3.   Based on my knowledge, the financial statements, and other financial
          information included in this annual report, fairly present in all
          material respects the financial condition, results of operations and
          cash flows of the registrant as of, and for, the periods presented in
          this annual report;

     4.   The registrant's other certifying officers and I are responsible for
          establishing and maintaining disclosure controls and procedures (as
          defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant
          and we have:

          a) designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this annual report
          is being prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this annual report (the "Evaluation Date"); and

          c) presented in this annual report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

     5.   The registrant's other certifying officers and I have disclosed, based
          on our most recent evaluation, to the registrant's auditors and the
          audit committee of registrant's board of directors (or persons
          performing the equivalent function):

          a) all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

          b) any fraud, whether or not material, that involves management or
          other employees who

<PAGE>

          have a significant role in the registrant's internal controls; and

     6.   The registrant's other certifying officers and I have indicated in
          this annual report whether or not there were significant changes in
          internal controls or in other factors that could significantly affect
          internal controls subsequent to the date of our most recent
          evaluation, including any corrective actions with regard to
          significant deficiencies and material weaknesses.

/s/ Joseph M. Paiva

Joseph M. Paiva
Chief Financial Officer

March 31, 2003


<PAGE>

                                                                    Exhibit 23.1


                          Independent Auditors' Consent
                          -----------------------------

The Board of Directors
Orthovita, Inc.


We consent to the incorporation by reference in the Registration Statement (Nos.
333-66681, 333-90981, 333-100034) on Form S-8 and in the Registration
Statement (Nos. 333-47386, 333-59288, 333-84632, 333-88334, 333-100341) on Form
S-3 of Orthovita, Inc. of our report dated February 11, 2003, with respect to
the consolidated balance sheet of Orthovita, Inc. as of December 31, 2002 and
the related consolidated statements of operations, shareholders' equity and
comprehensive income (loss) and cash flows for the year then ended, which report
appears in the December 31, 2002 annual report on Form 10-K of Orthovita, Inc.

/s/ KPMG LLP
Philadelphia, Pennsylvania
March 31, 2003